Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in Pozuelo De Alarcon – page 41

3 275 clinical trials in Pozuelo De Alarcon, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Pozuelo De Alarcon at a glance
3 275
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 275 trials in Pozuelo De Alarcon

Open in trial search

Study of bifikafusp alfa and onfekafusp alfa injected into tumors for patients with locally advanced basal cell carcinoma who progressed on or cannot tolerate systemic treatment

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bifikafusp Alfa
  • Sponsor:Philogen S.p.A.

Endometrial cancer+6

Recruiting

A Study Testing BNT329 Safety and Effectiveness in Patients With Advanced Solid Tumors That Express the CA19-9 Tumor Marker

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:BNT329
  • Sponsor:BioNTech SE

A Study of Danicamtiv for Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy to Test if it Improves Heart Function and Exercise Ability

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Danicamtiv
  • Sponsor:Kardigan Inc.

Myelofibrosis

Recruiting

A Study of Pacritinib for Reducing Bone Marrow Scarring in Patients with Myelofibrosis Who Have Low Platelet Counts

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pacritinib
  • Sponsor:Grupo Espanol De Enfermedades Mieloproliferativas Cronicas Ph

A Study of Intravenous Ferric Carboxymaltose on Quality of Life in Older Adults with Acute Coronary Syndrome and Iron Deficiency

Registered drugNo placebo
Countries:SpainSpain
  • Participants:65+ years
  • Substances:Ferric Carboxymaltose
  • Sponsor:Instituto De Investigacion Sanitaria Fundacion Para La Investigacion Del Hospital Clinico De Valencia-INCLIVA

Study of Izalontamab Brengitecan Compared to Platinum-Based Chemotherapy for Patients with Metastatic Urothelial Cancer After Immunotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of Revumenib and Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia with NPM1 Gene Mutation

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Syndax Pharmaceuticals Inc.

Breast cancer+3

Recruiting

A study testing zanidatamab combined with chemotherapy before surgery in patients with HER2-positive breast cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Jazz Pharmaceuticals Ireland Limited

A study to test the safety and effects of TLN-372 alone and with other cancer drugs in patients with advanced solid tumors with KRAS gene changes

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Treeline Biosciences Inc.

A study testing finerenone compared to placebo in patients with chronic kidney disease who are not taking renin-angiotensin-system inhibitors

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Universitair Medisch Centrum Groningen

Study of ivonescimab alone or with ligufalimab versus pembrolizumab for patients with recurrent or metastatic head and neck squamous cell cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Ivonescimab
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

A study comparing venetoclax, azacitidine, and quizartinib versus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia patients not suitable for standard chemotherapy

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Quizartinib Dihydrochloride
  • Sponsor:Fundacion Pethema

Other cities in Spain

The busiest research cities in the country

All 210 cities in Spain

Clinical research in Pozuelo De Alarcon

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on multiple cancer types including bladder cancer, pancreatic adenocarcinoma, and non-small cell lung cancer. Studies evaluate novel combination therapies and targeted treatments.

  • Advanced solid tumors
  • Metastatic melanoma
  • Gastric cancer

Research includes immunotherapy approaches and antibody-drug conjugates for improved treatment outcomes.

02 Respiratory Medicine

Clinical investigations in respiratory conditions, including studies of RSV prevention in high-risk infants and novel treatments for uncontrolled asthma. Research focuses on innovative therapeutic approaches.

  • COVID-19 vaccine development
  • Respiratory infections
  • Inflammatory airway diseases

Studies evaluate both preventive measures and treatment interventions.

03 Neurological Disorders

Research targeting neurological conditions, with emphasis on Alzheimer's Disease and Multiple Sclerosis. Studies focus on disease-modifying therapies and novel treatment approaches.

  • Early-stage Alzheimer's treatment
  • Relapsing MS therapies
  • Neurodegeneration

Investigations aim to slow disease progression and improve patient outcomes.

04 Hematology

Studies in blood disorders including acute myeloid leukemia and immune thrombocytopenia. Research evaluates new therapeutic approaches and combination treatments.

  • Leukemia treatments
  • Myelodysplastic syndrome
  • Platelet disorders

Focus on improving survival rates and treatment efficacy.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.